Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Published byOrsolya Törökné Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development."— Presentation transcript:

1 Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Probabilities of diabetes mellitus (DM) curves were compared using log-rank test (P<0.0001). Individuals at risk at each visit of follow-up were: 9306 (V0), 8230 (V1), 7524 (V2), 7178 (V3), 6582 (V4), 6229 (V5), 5572 (V6), 4876 (V7), 4275 (V8), 2931 (V9), and 510 (V10). William E Kraus et al. BMJ Open Diab Res Care 2018;6:e000523 ©2018 by American Diabetes Association

Download ppt "Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development."

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Diabetes hazard rates by number of visits with reported statin use.

Diabetes hazard rates by number of visits with reported statin use.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.
Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),

Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Enrollment and Outcomes

Enrollment and Outcomes
(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Similar presentations

Ads by Google